Drug updated on 11/13/2023
|Injection (intravenous; 60 mg/vial)
|Ongoing and Completed Studies
- Indicated for the treatment of adult patients with relapsed follicular lymphoma (FL) who have received at least two prior systemic therapies.
Product Monograph / Prescribing Information
|Aliqopa (copanlisib) Prescribing Information.
|Bayer Healthcare Pharmaceuticals Inc., Whippany, NJ
Systematic Reviews / Meta-Analyses
|Phosphatidylinositol 3 kinase inhibitor-related pneumonitis: a systematic review and meta-analysis.
|Expert review of clinical pharmacology
|Efficacy and safety of copanlisib in relapsed/refractory B-cell non-Hodgkin lymphoma: A meta-analysis of prospective clinical trials.
|Frontiers in Immunology
|Risk of cutaneous adverse events in cancer patients treated with phosphatidylinositol-3-kinase inhibitors: A systematic review and meta-analysis of randomized controlled trials.
|A systematic review of the management of relapsed/refractory follicular lymphoma.
|Nigerian Journal of Haematology
Clinical Practice Guidelines
|Newly diagnosed and relapsed follicular lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up.
|Annals of Oncology
|B-cell lymphomas, version 3.2019.
|Journal of the National Comprehensive Cancer Network